Pregled bibliografske jedinice broj: 1259620
Fulminant Fournier’s gangrene in a patient with gastric cancer treated with ramucirumab and paclitaxel
Fulminant Fournier’s gangrene in a patient with gastric cancer treated with ramucirumab and paclitaxel // Therapeutic Advances in Drug Safety, 11 (2020), 1-4 doi:10.1177/2042098620946556 (međunarodna recenzija, članak, stručni)
CROSBI ID: 1259620 Za ispravke kontaktirajte CROSBI podršku putem web obrasca
Naslov
Fulminant Fournier’s gangrene in a patient with
gastric cancer treated with ramucirumab and
paclitaxel
Autori
Rakušić, Zoran ; Mišir Krpan, Ana ; Sjekavica, Ivica
Izvornik
Therapeutic Advances in Drug Safety (2042-0986) 11
(2020);
1-4
Vrsta, podvrsta i kategorija rada
Radovi u časopisima, članak, stručni
Ključne riječi
Fournier’s gangrene ; gastric cancer ; paclitaxel ; ramucirumab
Sažetak
Fournier’s gangrene (FG) is an uncommon form of necrotizing fasciitis, localized on the external genital organs, perianal region, and abdominal wall, accompanied by thrombosis of the feeding arteries, leading to gangrene of the skin and subcutaneous tissue, with manifestations of rapid clinical progression and multiple organ failure. Ramucirumab is a recombinant human immunoglobulin G1 monoclonal antibody that binds to the extracellular binding domain of vascular endothelial growth factor receptor-2 (VEGFR-2) and prevents the binding of all VEGFR ligands. The literature describes bevacizumab, aflibercept, and regorafenib associated with FG in patients with colorectal cancer. According to our knowledge this is the first report of FG possibly related to ramucirumab in a patient with gastric cancer. If not recognized in time, it can lead to fatal complications.
Izvorni jezik
Engleski
Znanstvena područja
Temeljne medicinske znanosti
POVEZANOST RADA
Ustanove:
Medicinski fakultet, Zagreb,
Klinički bolnički centar Zagreb
Citiraj ovu publikaciju:
Časopis indeksira:
- Current Contents Connect (CCC)
- Web of Science Core Collection (WoSCC)
- Science Citation Index Expanded (SCI-EXP)
- SCI-EXP, SSCI i/ili A&HCI
- Scopus
